May 8, 2013
Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
April 29, 2013
Argos Therapeutics to Present at the 12th Annual Needham Healthcare Conference
March 13, 2013
Argos Therapeutics Welcomes Jean Lamarre to Board of Directors
March 4, 2013
Argos Therapeutics Validates Durability of AGS-003 Induced Immune Response in mRCC Patients
February 14, 2013
Argos Therapeutics Announces Updated Phase 2 Data for AGS-003 Personalized Immunotherapy for Metastatic Renal Cell Carcinoma
January 28, 2013
Argos Therapeutics to Present on Automated Manufacturing Process at 2013 Cell and Gene Therapy Forum
January 14, 2013
Argos Therapeutics Enrolls Initial Patients in Pivotal Phase 3 ADAPT Study
November 15, 2012
Argos Therapeutics Study Confirms Optimal Quality Control Methods for Production of its RNA-Based Immunotherapies
| 
